Lexeo Therapeutics, Inc. Common StockLXEONASDAQ
Loading
| Metric | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 |
|---|---|---|---|---|---|
| Revenue Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Gross Profit Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| EBITDA Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Operating Income Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Net Income Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| EPS Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| EPS Diluted Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Weighted Average Shares Growth | +31.36% | +21.10% | +18.35% | +32.03% | +84.44% |
| Weighted Average Shares Diluted Growth | +31.36% | +21.10% | +18.35% | +32.03% | +84.44% |
| Dividends per Share Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Operating Cash Flow Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Free Cash Flow Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Receivables Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Inventory Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Asset Growth | +217.71% | +5.10% | -41.05% | -8.30% | -17.27% |
| Book Value per Share Growth | +0.00% | -15.02% | -59.30% | -36.54% | -52.98% |
| Debt Growth | -35.82% | -14.73% | -16.35% | -17.87% | -18.71% |
| R&D Expense Growth | +35.82% | +123.70% | +9.08% | -11.11% | -32.99% |
| SG&A Expenses Growth | +168.25% | +33.29% | +120.35% | +128.43% | -33.21% |